Novo Nordisk Sues Eli Lilly Over GLP-1 Advertising Claims

Novo Nordisk Inc. has filed a lawsuit in the U.S. District Court for the District of New Jersey against Eli Lilly and Company and Lilly USA, LLC, alleging multiple violations of federal and state false advertising and unfair competition laws under the Lanham Act.

Details of the Lawsuit

The lawsuit targets Lilly's aggressive direct-to-consumer (DTC) advertising campaigns for its GLP-1 drugs, including Mounjaro and Zepbound, which are used for diabetes and weight loss. Novo Nordisk claims the ads contain misleading statements about the efficacy and safety of Lilly's products compared to its own drugs, such as Ozempic and Wegovy.

Company Response

Eli Lilly has denied the allegations, stating that its advertising is accurate and based on scientific evidence. The company has vowed to defend itself vigorously.

Precedents and Context

The lawsuit comes amid intense competition between the two pharmaceutical giants in the rapidly growing GLP-1 market. While both companies have previously run comparative ads, this is the first time their dispute has escalated to litigation.

Potential Financial Impact

If the court rules in Novo Nordisk's favor, Eli Lilly may be required to modify its advertising or pay damages. However, the financial impact is expected to be limited given the multi-billion-dollar annual sales of GLP-1 drugs.